The assay for serum antibody to the Salmonella typhi capsular polysaccharide (Vi) antigen has recently been revised because of the availabiity of a purified, highly polymerized Vi antigen. We compared this revised Vi antibody assay to the traditional one for potential usefulness in the surveillance of An alternative means of following typhoid carriers would be desirable. A serological test, serum antibody to the Vi capsular polysaccharide of S. typhi, has traditionally been associated with the persistence of S. typhi in the body after acute typhoid fever (2). However, previous studies showed that this test possessed neither the specificity nor the sensitivity for the condition of chronic typhoid carriage to have broad clinical usefulness (1, 3, 9, 14) .
The assay for serum antibody to the Salmonella typhi capsular polysaccharide (Vi) antigen has recently been revised because of the availabiity of a purified, highly polymerized Vi antigen. We compared this revised Vi antibody assay to the traditional one for potential usefulness in the surveillance of chronic enteric carriers of S. typhi. The purified Vi antigen of Citrobacter freundii was incorporated into a passive hemagglutination assay for serum Vi antibody; the standard Vi antibody assay was also a hemagglutination assay that employed as the Vi antigen a crude extract of Citrobacter (Ballerup O group 29). As determined by the revised assay, Vi antibody was found in the sera of 22 (71%) of 31 current typhoid carriers, none of 6 resolved carriers, and none of 22 control subjects. According to the traditional assay, Vi antibody was present in 23 of those current carriers (74%), 1 of the resolved carriers (17%), and 4 of the control subjects (18%). The rate of false-positive Vi antibody tests among resolved carriers and control subjects was less with the revised assay (P < 0.05). Successful antimicrobial therapy resulted in a reversion to seronegativity within 1 year in 8 of 10 Vipositive carriers according to the revised assay, but in only 3 of 11 according to the standard assay (P < 0.05). During a 2-year period of observation, 15 (94%) of 16 current typhoid carriers had at least one positive purified Vi antibody test; among 12 of those patients with Vi titers of 1:40 or greater, 9 (75%) were continuously Vi positive. Thus, the revised Vi antibody assay is more specific and no less sensitive than the standard assay for the condition of current enteric carriage of S. typhi. This serological test could be of value in the surveillance of typhoid carriers by public health agencies.
The asymptomatic enteric carrier of Salmonella typhi is a key link in the epidemiology of typhoid fever. The most recent statistics from the United States indicate that over 30% of cases can be traced directly to such a carrier (16) . The cornerstone of surveillance of typhoid carriers by public health agencies is the periodic culture of feces. Nevertheless, it is often difficult to obtain fecal specimens for this important test. Many typhoid carriers are elderly, poorly educated, and fail to understand the implications of their condition. In addition, most individuals have a natural aversion to handling their own feces. Consequently, typhoid carriers are frequently uncooperative when asked to submit fecal specimens for culture (18) .
An alternative means of following typhoid carriers would be desirable. A serological test, serum antibody to the Vi capsular polysaccharide of S. typhi, has traditionally been associated with the persistence of S. typhi in the body after acute typhoid fever (2) . However, previous studies showed that this test possessed neither the specificity nor the sensitivity for the condition of chronic typhoid carriage to have broad clinical usefulness (1, 3, 9, 14) .
The Vi antigen of S. typhi and that of Citrobacter freundii, which is antigenically identical to the former (19) , have recently been purified in a highly polymerized form during a search for an improved typhoid vaccine (20, 21 The Vi antigen of a C. freundii strain traditionally called Citrobacter 5396/38 was purified as previously described (20) . Briefly, the process involved the following three steps: (i) the removal of nucleic acids and proteins from acetone-killed and dried bacterial cells by treatment with deoxyribonuclease, ribonuclease, and pronase; (ii) concentration of the Vi polysaccharide by extraction with 60% ethanol; and (iii) separation of the Vi polysaccharide from residual somatic antigens by precipitation with 0.1% hexadecyltrinethylammonium bromide. In double-gel diffusion studies with antiserum to Citrobacter 5396/38 and S. typhi strain Ty-2, this purified Vi antigen gave one sharp, narrow precipitin band (20) .
The crude Vi antigen was prepared by incubating Citrobacter (Ballerup O group 29) on infusion agar overnight. The bacteria were harvested in 0.15 M NaCI and steamed for 1 h. After cooling, the suspension of killed bacteria was centrifuged, and the supernatant fluid containing the Vi antigen was decanted and stored at -20°C.
A passive hemagglutination assay was used to measure serum antibodies to the crude and purified Vi antigens (17) . Sheep erythrocytes were sensitized with the crude Vi antigen in a 1:400 dilution of the NaCI extract and with the purified Vi antigen at a concentration of 10 In the control group, all 22 stool cultures were negative for S. typhi, and all sera were negative for typhoid O and H agglutinins. Likewise, all were negative for purified Vi antibody, but four of them (18%) contained crude Vi antibody in titers ranging from 1:20 to 1:80. Thus, the overall false-positive rates of the two Vi tests among resolved carriers and controls were 0% (0 of 28) for the purified Vi test and 18% (5 of 28) for the crude Vi test (P < 0.05; x2 analysis) (11) . Serum specimens were periodically tested in random fashion in a hemagglutination assay that employed the purified Vi antigen of S. typhi (21) as the sensitizing agent. Antibody titers obtained in these assays agreed within one tube dilution with those in the assay with the Citrobacter Vi antigen in over 95% of specimens.
The purified Vi antibody titer reverted to negative within 1 year of successful antimicrobial therapy in all eight carriers who had an initial titer of 1:640 or less (Fig. 1) . During that same period of time, the crude Vi antibody titer declined in most patients but became negative in only 3 of 11 patients in whom it was originally positive (P< 0.05; Fisher exact test) (11) . Among five carriers who failed to be cured by antimicrobial therapy, both types of Vi antibody, if initially positive, remained positive with a minor change in titer.
A total of 26 current carriers were initially enrolled in the prospective study that sought to correlate stool culture results and purified Vi antibody; 18 submitted at least three paired specimens of feces and sera during the 2-year period and were considered to be evaluable. Among the remainder, one patient who submitted specimens only at the beginning and end of the 2-year period was also included because she had been a constant excretor of S. typhi for 14 years and was undoubtedly a current carrier.
Among the 12 current typhoid carriers who had at least one purified Vi titer of 1:40 during the prospective study, 9 (75%) had all serum specimens positive for purified Vi antibody (Table 2). None of the four whose highest purified Vi titers were less than 1:40 were persistently Vi positive. Altogether, 15 of 16 current carriers had at least one positive Vi antibody test during the period of observation. As all three resolved carriers were continuously Vi antibody negative, the predicted value (8) of the purified Vi antibody test in the diagnosis of current typhoid carriage during this 2-year period was 95%.
DISCUSSION
The surface antigen of S. typhi designated Vi is a linear homopolymer of N-acetyl, O-acetylpolygalacturonic acid. This acidic polysaccharide, which lies exterior to the bacterial cell wall, is thus analogous in location and biochemical composition to the Escherichia coli K antigens (15) and probably serves a purpose similar to those and other polysaccharide capsular or envelope antigens, namely, acting as a deterrent to host defense systems such as complement-mediated bacterial lysis (13) and phagocytosis (10) . Antibodies to the Vi antigen appear in serum during the course of convalescence from typhoid fever in approximately 80% of cases (4) . Likewise, typhoid vaccination evokes a Vi antibody response in 85% of patients. In carriers such as these, it should be possible to reduce the frequency of stool cultures and to perform Vi serology at intervening intervals. Reversion from Vi seropositivity to Vi seronegativity on two successive specimens should prompt an evaluation for a spontaneous cessation of typhoid carriage, a phenomenon that is well described (6) . Vi serology could also be applied to the detection of an asymptomatic typhoid carrier during the evaluation of a sporadic case of typhoid fever. In Arkansas, over 75% of cases of typhoid fever are associated with an undiagnosed enteric carrier (unpublished observations). Such an evaluation may involve culturing the stool specimens of as many as 10 individuals who are intimate contacts of the patient with typhoid fever. A simple screening procedure that is sufficiently sensitive and specific could be very useful in such evaluations, which consume a great deal of time and effort on the part of public health agencies. The main limitation of the crude Vi test in this circumstance is its lack of specificity; up to 50% of certain control populations were found to be Vi positive by this method (3, 4, 9) . Our results on a small group of matched control subjects suggest that in this geographic region, the purified Vi antibody test is more specific for the condition of current typhoid carriage than is the crude Vi antibody test. Consequently, the former is currently being investigated prospectively in the screening for new typhoid carriers.
